Novartis ends mid-stage Fabhalta trial targeting serious kidney condition (Reuters) - Oct 16, 2026 - "Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious kidney condition, citing 'strategic considerations', according to a federal clinical trials registry....The government database, last updated on October 15, shows Novartis decided to conclude the study after completing the first part; It gives no other explanation and does not say whether safety or effectiveness played a role"
Trial termination • Glomerulonephritis • Lupus Nephritis
|